U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H11Cl2NO4
Molecular Weight 328.147
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DILOXANIDE FUROATE

SMILES

CN(C(=O)C(Cl)Cl)C1=CC=C(OC(=O)C2=CC=CO2)C=C1

InChI

InChIKey=BDYYDXJSHYEDGB-UHFFFAOYSA-N
InChI=1S/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3

HIDE SMILES / InChI
Molecular Formula C14H11Cl2NO4
Molecular Weight 328.147
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Diloxanide (used in the form of furoate) was developed for the treatment of intestinal amoebiasis. The effectiveness of the drug was proved in clinical trials, however, the mechanism of its action is unknown. The drug is not marketed in the United States, athough it is available in India.

Originator

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
DILOXANIDE FUROATE

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
activator
150

inhibitor
2252
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
BCRP
910

CYP2C19
2057

CYP1A2
2153

P-gp
1741

UMAT
30

CYP19A1
429
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 inconclusive [EC50 15.8489 uM]
CYP2C19
2141
 inconclusive [IC50 9.7717 uM]
CYP3A4
2633
 no [IC50 15.8489 uM]
BCRP
985
 no
CYP19A1
430
 no
CYP1A2
2333
 no
CYP2D6
2546
 no
MRP1
232
 no
P-gp
1932
 no
UMAT
30
 no
CYP2C9
2497
 yes [IC50 15.4871 uM]
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
Difficulties in the treatment of intestinal amoebiasis in mentally disabled individuals at a rehabilitation institution for the intellectually impaired in Japan.
2010
RPLC Determination of Tinidazole and Diloxanide Furoate in Tablets.
2008-09
Invasive amoebiasis complicating iflammatory bowel disease.
2007-12-01
Stability studies on diloxanide furoate: effect of pH, temperature, gastric and intestinal fluids.
2004-04
Patents

Patents

WO2011047439 A1
2

Sample Use Guides

In Vivo Use Guide
500mg 3 times daily for 5 days or 20mg/kg/daily divided into 3 daily doses for 10 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:13 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:13 GMT 2025
Record UNII
YP4N72IW34
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NSC-759146
Preferred Name English
DILOXANIDE FUROATE
MART.   MI   USP   USP-RS   WHO-DD   WHO-IP  
Common Name English
DILOXANIDI FUROAS [WHO-IP LATIN]
Common Name English
DILOXANIDE FUROATE [MI]
Common Name English
DICHLOFURAZOL
Common Name English
2,2-Dichloroacetamido-4-N-methylphenyl 2-furoate
Common Name English
DILOXANIDE FUROATE [USP-RS]
Common Name English
DILOXANIDE FUROATE [MART.]
Common Name English
FURENTOMIN
Common Name English
DILOXANIDE FUROATE [WHO-IP]
Common Name English
Diloxanide furoate [WHO-DD]
Common Name English
DILOXANIDE FUROATE [USP MONOGRAPH]
Common Name English
4-(N-METHYL-2,2-DICHLOROACETAMIDO)PHENYL 2-FUROATE
Systematic Name English
HISTOMIBAL
Common Name English
Code System Code Type Description
MESH
C004932
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
DRUG CENTRAL
896
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DILOXANIDE FUROATE
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY Description: A white or almost white, crystalline powder; odourless.Solubility: Very slightly soluble in water; soluble in 100 parts of ethanol (~750 g/l) TS and in 130 parts of ether R.Category: Antiamoebic drug.Storage: Diloxanide furoate should be kept in a well-closed container, protected from light.Requirements : Definition. Diloxanide furoate contains not less than 98.0% and not more than 102.0% of C14H11Cl2NO4, calculated withreference to the dried substance.
RXCUI
23203
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID8048999
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
WIKIPEDIA
DILOXANIDE FUROATE
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
DRUG BANK
DB08792
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
CHEBI
4601
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
SMS_ID
100000087510
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
EVMPD
SUB01735MIG
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
CAS
3736-81-0
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL1334860
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
223-108-1
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
PUBCHEM
19529
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
MERCK INDEX
m4493
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY Merck Index
NSC
759146
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
RS_ITEM_NUM
1204805
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
FDA UNII
YP4N72IW34
Created by admin on Mon Mar 31 17:34:13 GMT 2025 , Edited by admin on Mon Mar 31 17:34:13 GMT 2025
PRIMARY
Related Record Type Details
Structure of DILOXANIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966